Tagged With Immunotherapy

New hope for peanut allergy sufferers as pioneering study suggests immunotherapy treatment could reduce the severity of reactions


Are allergy shots worth it? They can provide long-term allergy relief — here's whether it's right for you


Gilead just made a $4.9 billion bet on cancer-drug maker Forty Seven, whose stock skyrocketed 62%



How the researchers who won the Nobel Prize in medicine transformed the way we treat cancer


The FDA just approved a new treatment for a common form of skin cancer


A company that's taking a new approach to tackling Alzheimer's is moving into human trials after raising $133 million



A cutting-edge new cancer treatment has two different price tags, and it could be the future of how we pay for drugs


A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to treat more patients


'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change how we treat the disease


2 cancer drugmakers just presented key data about how new treatments work in lung cancer -- and the markets picked a winner


We're about to get some key lung cancer data -- and it could affect how hundreds of thousands of cancer patients are treated


A cancer drugmaker just failed a key trial and its stock is crashing



A CEO who sold his last cancer drug company for $12 billion just got $300 million to do it again


America's top cancer official has a plan to fix one of the biggest limits to finding new cancer treatments


An experimental treatment for peanut allergies just succeeded in a key trial


Bristol-Myers Squibb just claimed 'a breakthrough in cancer research' -- but there's a catch



A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved


Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsement


Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy


A former biotech executive who's living with terminal cancer wants to reset expectations about new cancer treatments